stockrowGlaukos Corporation
GKOS Healthcare Medical Devices
Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.
- Revenue
- +58.0%
- EPS
- +110.7%
- Free cash flow
- +411.2%
- Total debt
- −2.25%
Quarter to September 2026, against a year earlier
Follow GKOS
Alert me
Glaukos Corporation (GKOS) EPS (diluted)
Glaukos Corporation's EPS (diluted) for fiscal 2025 was −$3.28, compared with −$2.77 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$2.94. Over the past ten years it has ranged from −$3.28 (fiscal 2025) to $0.37 (fiscal 2019) — the current reading is the lowest in ten years. Glaukos Corporation ranks 115th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$3.28 | — |
| FY2024 | −$2.77 | — |
| FY2023 | −$2.78 | — |
| FY2022 | −$2.09 | — |
| FY2021 | −$1.07 | — |
| FY2020 | −$2.70 | — |
| FY2019 | $0.37 | — |
| FY2018 | −$0.37 | — |
| FY2017 | $0.00 | — |
| FY2016 | $0.12 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.03 | — |
| Jun 2026 | −$0.31 | — |
| Mar 2026 | −$0.34 | — |
| Dec 2025 | −$2.32 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| BIO.B Bio-Rad Laboratories, Inc. compare | $37.97 |
| BIO Bio-Rad Laboratories, Inc. compare | $37.97 |
| PODD Insulet Corporation compare | $6.14 |
| GMED Globus Medical, Inc. compare | $4.07 |
| PEN Penumbra, Inc. compare | $3.97 |
| ZBH Zimmer Biomet Holdings, Inc. compare | $3.96 |
| SNN Smith & Nephew SNATS, Inc. compare | $1.13 |
| BRKR Bruker Corporation compare | −$1.01 |
| GKOS Glaukos Corporation | −$2.94 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on GKOS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement